Introduction
Dyslipidemias are among the most frequently identified and treated chronic illnesses. Research on dyslipidemias is still ongoing and continues to expand; recent studies have provided insights into their genetic and molecular origins, as well as their role in the development of atherosclerosis.1 Over the last few decades, progress in genetics, analytical tools, and knowledge of signaling molecules has revealed a wide range of new mechanisms that can be targeted for therapy to reduce cholesterol levels.2 Rapid progress has been made in developing advanced methods that use small molecules, biological agents, or nucleic acids to target these recently identified mediators. Selective suppression of the synthesis of particular proteins is now achievable due to the engineering of antisense RNA and small…